Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 20/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180262 | 0.89 | CYP3A4 (0.73) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6349099 | 0.88 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL3274522 | 0.86 | CYP3A4 (0.74) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1816215 | 0.85 | CYP3A4 (0.86) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1138350 | 0.85 | CYP3A4 (0.72) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL31706363 | 0.83 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4591548 | 0.83 | CYP3A4 (0.76) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL3274128 | 0.83 | CYP3A4 (0.76) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4886755 | 0.83 | CYP3A4 (0.82) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL23965746 | 0.82 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696671-B2 | Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20190152971-A1 | Imidazo[1,2-A]Pyridine Derivatives, Methods for Preparing the Same and Use Thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2019-05-23 | — | — | US | disclosed |
| US-8993589-B2 | Imidazopyridine derivatives which inhibit the secretion of gastric acid | CLARET EUROPEAN SPECIALTY LENDING COMPANY IV, S.A R.L. (LU) | 2015-03-31 | — | — | US | disclosed |
| US-20140235666-A1 | IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID | CLARET EUROPEAN SPECIALTY LENDING COMPANY IV, S.A R.L. (LU) | 2014-08-21 | — | — | US | disclosed |
| US-8669269-B2 | Imidazopyridine derivatives which inhibit the secretion of gastric acid | CLARET EUROPEAN SPECIALTY LENDING COMPANY IV, S.A R.L. (LU) | 2014-03-11 | — | — | US | disclosed |
| EP-2365975-B1 | IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID | DAHLSTROEM MIKAEL (FI) | 2013-03-13 | — | — | EP | disclosed |
| US-20110237619-A1 | IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID | CLARET EUROPEAN SPECIALTY LENDING COMPANY IV, S.A R.L. (LU) | 2011-09-29 | — | — | US | disclosed |
| EP-2365975-A1 | IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID | Dahlström, Mikael (FI) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010063876-A1 | IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID | DAHLSTROEM MIKAEL (FI) | 2010-06-10 | — | — | WO | disclosed |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | ELMAN BJORN | 2009-10-01 | — | — | US | disclosed |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | ELMAN BJORN | 2009-10-01 | — | — | US | disclosed |
| US-20060063797-A1 | Process for preparing a substituted imidazopyridine compound | ELMAN BJORN | 2006-03-23 | — | — | US | disclosed |
| US-6900324-B2 | Process for preparing a substituted imidazopyridine compound | ASTRAZENECA AB (SE) | 2005-05-31 | — | — | US | disclosed |
| EP-1317455-B9 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| EP-1317455-B1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | ASTRAZENECA AB (SE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040039013-A1 | Process for preparing a substituted imidazopyridine compound | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | US | disclosed |
| EP-1317455-A1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020523-A1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063797-A1 | Process for preparing a substituted imidazopyridine compound | NISCH, CYP1B1, CYP1A2 | CYP3A4 8/4885CYP2C9 121/4885CYP2D6 24/4885 |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | NISCH, CYP1A2, CYP1B1 | CYP3A4 13/4885CYP2C9 133/4885CYP2D6 23/4885 |
| US-20040039013-A1 | Process for preparing a substituted imidazopyridine compound | CYP1B1, BRD1, SKP1 | CYP3A4 24/4885CYP2C9 261/4885CYP2D6 17/4885 |
| US-10696671-B2 | Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof | HRH2, GIPR, HRH4 | CYP3A4 145/4885CYP2C9 477/4885CYP2D6 327/4885 |
| US-20110237619-A1 | IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID | HRH2, GIPR, HRH4 | CYP3A4 224/4885CYP2C9 293/4885CYP2D6 478/4885 |
| US-20190152971-A1 | Imidazo[1,2-A]Pyridine Derivatives, Methods for Preparing the Same and Use Thereof | GIPR, PGC, VIP | CYP3A4 987/4885CYP2C9 1375/4885CYP2D6 2024/4885 |
| US-20140235666-A1 | IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID | HRH2, GIPR, HRH4 | CYP3A4 224/4885CYP2C9 293/4885CYP2D6 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.